SCHEMBL4707336

SCHEMBL4707336

CCn1nc(-c2ccccc2)c(C(=O)OC)c(Nc2cccc(F)c2)c1=O

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 3/20 0.56
ALOX5 P09917 1/20 0.44
TP53 P04637 4/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
DHODH Q02127 1/20 0.41
PDE4A P27815 2/20 0.41
PDE4C Q08493 2/20 0.41
PDE4D Q08499 2/20 0.41
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
MAPT P10636 4/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4706135 0.91 PDE4B (0.62) PDE4BTP53SMN1; SMN2DHODHPDE4A
SCHEMBL4706107 0.90 PDE4B (0.70) PDE4BTP53SMN1; SMN2
SCHEMBL4708343 0.88 PDE4B (0.56) PDE4BALOX5TP53LMNASMN1; SMN2
SCHEMBL4708777 0.85 PDE4B (0.62) PDE4BSMN1; SMN2MEN1KMT2A
SCHEMBL4054904 0.83 PDE4B (0.57) PDE4BTP53LMNASMN1; SMN2MEN1
SCHEMBL1653670 0.82 PDE4B (0.59) PDE4BSMN1; SMN2KMT2A
SCHEMBL4705746 0.82 PDE4B (0.72) PDE4BTP53SMN1; SMN2PDE4APDE4C
SCHEMBL4707603 0.81 PDE4B (0.55) PDE4BALOX5TP53SMN1; SMN2DHODH
SCHEMBL4709794 0.81 PDE4B (0.57) PDE4BSMN1; SMN2MEN1KMT2APDE4A
SCHEMBL3033125 0.81 PDE4B (0.48) PDE4BLMNASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 US disclosed
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 US disclosed
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-03-09 US disclosed
EP-1503992-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS Almirall Prodesfarma, S.A. (ES) 2005-02-09 EP disclosed
WO-2003097613-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS ALMIRALL PRODESFARMA SA (ES) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B PDE4B 3/4885ALOX5 1378/4885TP53 4836/4885
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors PDE4A, PDE3A, PDE4B PDE4B 3/4885ALOX5 1378/4885TP53 4836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.